# Underdog Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/underdog-pharmaceuticals

- Industry: Healthcare
- Headquarters: Mountain View, US
- Website: www.underdogpharma.com
- Total disclosed funding: $4M
- Latest round: Seed (Nov 14, 2019)
- Investors on record: 1

## About

Underdog Pharmaceuticals, Inc. is dedicated to advancing healthcare by developing innovative drug therapies that target age-related diseases, offering solutions for cardiovascular health through unique therapeutic approaches.Underdog Pharmaceuticals, Inc. specializes in creating drug therapies to combat age-related diseases. Founded in 2019 by Amelia Anderson, Matthew O'Connor, and Michael Kope, the company is headquartered in Mountain View, US. The company raised USD 3.95 mn in a Seed funding round on November 14, 2019, led by KIZOO Technology Ventures, with no reported changes in its operational strategy since inception. Currently, it has secured a total of USD 3.95 mn in funding with one deal.Underdog Pharmaceuticals, Inc. focuses on the development of innovative drug therapies aimed at treating age-related diseases, specifically targeting atherosclerosis, heart attacks, and strokes. The company’s core offerings utilize novel derivatives of a recognized safe compound that works by removing arterial plaque and clearing non-degradable cholesterol from artery wall cells. This technology provides a preventive approach to cardiovascular health and is primarily targeted at healthcare providers and patients in the United States and Europe, emphasizing accessible and affordable treatment solutions.Underdog Pharmaceuticals, Inc. generates revenue through direct-to-consumer sales as well as partnerships with healthcare providers. The company employs a subscription model or direct sales strategy to offer their innovative therapies to healthcare entities. Pricing structures are designed to be accessible for both individual consumers and institutional clients, aligning with the demand for effective treatment options in the cardiovascular market.With recent funding of USD 3.95 mn secured in November 2019, Underdog Pharmaceuticals, Inc. aims to advance its product development and expand its market reach. The company plans to introduce new products targeting cardiovascular health and aims to enter additional markets within the US and Europe by 2022. The funding will support the company's initiatives to enhance product development and facilitate expansion into these targeted regions.

## Funding rounds

- Seed, Nov 14, 2019, $4M — KIZOO Technology Ventures

## Investors

- KIZOO Technology Ventures (https://capitalatlas.ai/funds/kizoo-technology-ventures) — Seed